Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-Aminoethoxydiphenylborate (commonly abbreviated as AAPB or more widely as 2-APB) is an organoboron compound used primarily in research settings. It acts as a modulator of intracellular calcium signaling by inhibiting inositol trisphosphate (IP3) receptors and various transient receptor potential (TRP) channels. At higher concentrations it can activate certain TRP channels such as TRPV1, TRPV2, and TRPV3. Additionally, it inhibits gap junctions formed by connexin proteins and modifies store-operated calcium channel (SOC) function—low concentrations enhance SOC activity while high concentrations cause transient activation followed by inhibition. Its lack of specificity limits its use for some experimental applications[10][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-aminoethoxydiphenylborate.